查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1947883

攝護腺健康市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、設備、最終用戶、功能、安裝類型、設備分類

Prostate Health Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Device, End User, Functionality, Installation Type, Equipment
出版日期: | 出版商: Global Insight Services | 英文 322 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計攝護腺健康市場規模將從2024年的355億美元成長到2034年的618億美元，複合年成長率約為5.1%。前列腺健康市場涵蓋旨在診斷、治療和管理前列腺相關疾病（包括良性前列腺增生和前列腺癌）的產品和服務，包括藥物、微創手術和診斷工具。前列腺疾病盛行率的不斷上升和公眾意識的提高正在推動治療方法的創新。對早期檢測和個人化醫療的重視正在塑造市場動態，並推動影像診斷技術和生物標記研究的發展。

前列腺健康市場正經歷強勁成長，這主要得益於公眾意識的提高和治療方法的進步。製藥業是推動市場成長的主要力量，荷爾蒙療法和化療藥物已成為前列腺疾病治療的關鍵手段。生物製藥和免疫療法藥物的重要性日益凸顯，反映了精準醫療的發展趨勢。診斷產業緊隨其後，磁振造影（MRI）和超音波等影像技術在前列腺健康的早期檢測和後續觀察中發揮關鍵作用。基因檢測和生物標記分析正逐漸成為風險評估和治療方案製定的有效工具。外科手術領域，尤其是微創手術（如機器人輔助手術），因其更高的精準度和更短的恢復時間而備受關注。積極的後續觀察和生活方式管理也正成為綜合前列腺健康策略的重要組成部分。遠端醫療和數位健康平台的創新正在促進遠端監測和病人參與，進一步推動市場成長。對預防保健和早期療育的重視將繼續塑造市場動態。

市場區隔
類型 良性攝護腺增生、攝護腺癌、攝護腺炎
產品 藥品、手術器材、診斷測試、營養補充品、攝護腺保健食品
服務 篩檢服務、諮詢服務、治療服務、監測服務、復健服務
科技 核磁振造影、超音波、切片檢查設備、PSA檢測、基因組檢測
適用的 醫院、診所、門診手術中心、居家醫療、研究機構
醫療設備 雷射設備、冷凍治療設備、射頻消融術設備
最終用戶 醫療保健提供者、患者和研究機構
功能 診斷、治療與預防
安裝類型 攜帶式和固定式
裝置 診斷影像設備、手術設備、監護設備

前列腺健康市場正經歷市場佔有率的動態變化，現有企業保持著主導地位，而新參與企業則不斷推出創新解決方案。先進治療方法和診斷工具的引入導致定價策略競爭日益激烈。近期推出的產品，主要集中在微創手術和個人化醫療方面，體現了以患者為中心的醫療服務趨勢。這種發展加劇了市場競爭，並促使各公司加強研發投入，以增​​強其產品陣容。攝護腺健康市場的競爭異常激烈，主要企業互相參照，力求競爭優勢。監管因素，尤其是在北美和歐洲，對市場動態的塑造至關重要，嚴格的指導方針影響產品核可和市場准入。各公司正透過加大合規和品質保證方面的投入來應對這些監管要求。由於技術進步、前列腺疾病盛行率的上升以及對早期檢測和治療日益重視，該市場有望實現成長。

主要趨勢和促進因素：

由於公眾意識的提高和醫療技術的進步，前列腺健康市場正經歷強勁成長。主要趨勢包括微創治療方法的廣泛應用以及針對前列腺疾病的新型治療方法的研發。這些創新對醫療服務提供者極具吸引力，因為它們能夠改善患者預後並縮短復原時間。此外，全球人口老化也是一個重要的促進因素。由於攝護腺健康問題在老年男性中更為普遍，這種人口結構變化正在推動對有效診斷和治療方案的需求。新興市場醫療保健支出的成長和醫療服務可近性的提高進一步促進了市場擴張。此外，研發投入的增加正在推動人們對攝護腺健康的認知取得突破性進展，從而為更具針對性和個人化的治療方案鋪平道路。專注於創新解決方案和策略合作的公司能夠更好地掌握這些機遇，確保攝護腺健康市場的持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 良性攝護腺增生
    • 攝護腺癌
    • 攝護腺炎
  • 市場規模及預測：依產品分類
    • 藥物
    • 外科器械
    • 診斷測試
    • 補充
    • 前列腺保健食品
  • 市場規模及預測：依服務分類
    • 篩檢服務
    • 諮詢服務
    • 治療服務
    • 監控服務
    • 復健服務
  • 市場規模及預測：依技術分類
    • MRI
    • 超音波
    • 切片檢查裝置
    • PSA檢測
    • 基因組檢測
  • 市場規模及預測：依應用領域分類
    • 醫院
    • 臨床科
    • 門診手術中心
    • 居家醫療
    • 研究所
  • 市場規模及預測：依設備分類
    • 雷射設備
    • 冷凍療法設備
    • 射頻消融裝置
  • 市場規模及預測：依最終用戶分類
    • 醫療保健提供者
    • 病人
    • 研究機構
  • 市場規模及預測：依功能分類
    • 診斷
    • 透過治療方法
    • 預防
  • 市場規模及預測：依安裝類型分類
    • 可攜式的
    • 固定的
  • 市場規模及預測：依設備分類
    • 診斷影像設備
    • 手術器械
    • 監測設備

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Astellas Pharma
  • Ferring Pharmaceuticals
  • Myriad Genetics
  • Tolmar Pharmaceuticals
  • Veru
  • Sophiris Bio
  • Nymox Pharmaceutical
  • Spectrum Pharmaceuticals
  • Advanced Accelerator Applications
  • Bavarian Nordic
  • Progenics Pharmaceuticals
  • Onco Genex Pharmaceuticals
  • Nant Kwest
  • Amgen Biosimilars
  • Dendreon Pharmaceuticals
  • Endo Pharmaceuticals
  • Astra Zeneca Biosimilars
  • Bristol Myers Squibb Biosimilars
  • Novartis Biosimilars
  • Sanofi Biosimilars

第9章：關於我們

簡介目錄
Product Code: GIS21014

Prostate Health Market is anticipated to expand from $35.5 billion in 2024 to $61.8 billion by 2034, growing at a CAGR of approximately 5.1%. The Prostate Health Market encompasses products and services aimed at diagnosing, treating, and managing prostate-related conditions, including benign prostatic hyperplasia and prostate cancer. This market includes pharmaceuticals, minimally invasive procedures, and diagnostic tools. Rising prevalence of prostate disorders and increasing awareness drive innovation in treatment options. Emphasis on early detection and personalized medicine shapes market dynamics, fostering advancements in imaging technologies and biomarker research.

The Prostate Health Market is experiencing robust growth, propelled by increasing awareness and advancements in treatment modalities. The pharmaceutical segment leads performance, with hormone therapy and chemotherapy drugs being pivotal in addressing prostate conditions. Biologics and immunotherapy drugs are gaining prominence, reflecting a shift towards personalized medicine. The diagnostic segment follows, with imaging techniques such as MRI and ultrasound playing a crucial role in early detection and monitoring of prostate health. Genetic testing and biomarker analysis are emerging as valuable tools for risk assessment and treatment planning. The surgical segment, particularly minimally invasive procedures like robotic-assisted surgery, is gaining traction due to enhanced precision and reduced recovery times. Active surveillance and lifestyle management are also becoming integral to comprehensive prostate health strategies. Innovations in telemedicine and digital health platforms are facilitating remote monitoring and patient engagement, further driving market growth. The focus on preventative care and early intervention continues to shape the market dynamics.

Market Segmentation
TypeBenign Prostatic Hyperplasia, Prostate Cancer, Prostatitis
ProductMedications, Surgical Devices, Diagnostic Tests, Supplements, Prostate Health Foods
ServicesScreening Services, Consultation Services, Treatment Services, Monitoring Services, Rehabilitation Services
TechnologyMRI, Ultrasound, Biopsy Devices, PSA Testing, Genomic Testing
ApplicationHospitals, Clinics, Ambulatory Surgical Centers, Home Care, Research Institutes
DeviceLaser Devices, Cryotherapy Devices, Radiofrequency Ablation Devices
End UserHealthcare Providers, Patients, Research Organizations
FunctionalityDiagnostic, Therapeutic, Preventive
Installation TypePortable, Fixed
EquipmentImaging Equipment, Surgical Equipment, Monitoring Equipment

The Prostate Health Market is experiencing a dynamic shift in market share, with established players maintaining dominance while new entrants introduce innovative solutions. Pricing strategies are competitive, driven by the introduction of advanced therapies and diagnostic tools. Recent product launches focus on minimally invasive procedures and personalized medicine, reflecting a trend towards patient-centric care. This evolution is fostering a competitive landscape, encouraging companies to invest in research and development to enhance their product offerings. Competition in the Prostate Health Market is intense, with key players benchmarking against each other to gain a competitive edge. Regulatory influences, particularly in North America and Europe, are critical in shaping market dynamics, with stringent guidelines affecting product approvals and market entry. Companies are navigating these regulations by investing in compliance and quality assurance. The market is poised for growth, driven by technological advancements, increasing prevalence of prostate disorders, and a growing emphasis on early detection and treatment.

Geographical Overview:

The prostate health market is witnessing diverse growth across global regions, each presenting unique opportunities. North America leads with advanced healthcare infrastructure and high awareness about prostate health. Increased government initiatives and research funding further drive the market. Europe follows, with a strong focus on early diagnosis and innovative treatment options. The region's robust healthcare policies enhance market expansion. Asia Pacific emerges as a lucrative growth pocket, propelled by rising healthcare expenditures and growing awareness about men's health. Countries like China and India are at the forefront, investing in healthcare advancements and expanding access to medical services. Latin America shows potential, with Brazil and Mexico enhancing healthcare systems and increasing prostate health awareness. The Middle East & Africa are gradually recognizing the importance of prostate health, with countries like the UAE investing in healthcare infrastructure and public health campaigns to address this crucial issue.

The imposition of global tariffs, coupled with geopolitical uncertainties, is significantly influencing the Prostate Health Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are navigating these challenges by investing in local research and development to mitigate dependency on imported medical technologies. China is accelerating its focus on domestic innovation in response to trade restrictions, aiming to bolster its healthcare industry. Taiwan, while a key player in medical device manufacturing, must carefully balance its economic ties amidst US-China tensions. The global prostate health market is experiencing steady growth, driven by rising awareness and technological advancements, with expectations of significant expansion by 2035. Middle East conflicts continue to pose risks to global supply chains and energy prices, potentially affecting production costs and timelines.

Key Trends and Drivers:

The prostate health market is experiencing robust growth, driven by increasing awareness and advancements in medical technologies. Key trends include the rise of minimally invasive treatments and the development of novel therapeutics targeting prostate conditions. These innovations are improving patient outcomes and reducing recovery times, making them highly attractive to healthcare providers. Additionally, the aging global population is a significant driver, as prostate health issues are more prevalent among older men. This demographic shift is fueling demand for effective diagnostic and treatment solutions. Increased healthcare spending and improved access to medical services in emerging markets are further contributing to market expansion. Moreover, growing investment in research and development is leading to breakthroughs in understanding prostate health, paving the way for more targeted and personalized treatment options. Companies focusing on innovative solutions and strategic partnerships are well-positioned to capitalize on these opportunities, ensuring sustained growth in the prostate health market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Installation Type
  • 2.10 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Benign Prostatic Hyperplasia
    • 4.1.2 Prostate Cancer
    • 4.1.3 Prostatitis
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Medications
    • 4.2.2 Surgical Devices
    • 4.2.3 Diagnostic Tests
    • 4.2.4 Supplements
    • 4.2.5 Prostate Health Foods
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Screening Services
    • 4.3.2 Consultation Services
    • 4.3.3 Treatment Services
    • 4.3.4 Monitoring Services
    • 4.3.5 Rehabilitation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 MRI
    • 4.4.2 Ultrasound
    • 4.4.3 Biopsy Devices
    • 4.4.4 PSA Testing
    • 4.4.5 Genomic Testing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Ambulatory Surgical Centers
    • 4.5.4 Home Care
    • 4.5.5 Research Institutes
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Laser Devices
    • 4.6.2 Cryotherapy Devices
    • 4.6.3 Radiofrequency Ablation Devices
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Healthcare Providers
    • 4.7.2 Patients
    • 4.7.3 Research Organizations
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Diagnostic
    • 4.8.2 Therapeutic
    • 4.8.3 Preventive
  • 4.9 Market Size & Forecast by Installation Type (2020-2035)
    • 4.9.1 Portable
    • 4.9.2 Fixed
  • 4.10 Market Size & Forecast by Equipment (2020-2035)
    • 4.10.1 Imaging Equipment
    • 4.10.2 Surgical Equipment
    • 4.10.3 Monitoring Equipment

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Installation Type
      • 5.2.1.10 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Installation Type
      • 5.2.2.10 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Installation Type
      • 5.2.3.10 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Installation Type
      • 5.3.1.10 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Installation Type
      • 5.3.2.10 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Installation Type
      • 5.3.3.10 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Installation Type
      • 5.4.1.10 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Installation Type
      • 5.4.2.10 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Installation Type
      • 5.4.3.10 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Installation Type
      • 5.4.4.10 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Installation Type
      • 5.4.5.10 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Installation Type
      • 5.4.6.10 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Installation Type
      • 5.4.7.10 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Installation Type
      • 5.5.1.10 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Installation Type
      • 5.5.2.10 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Installation Type
      • 5.5.3.10 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Installation Type
      • 5.5.4.10 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Installation Type
      • 5.5.5.10 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Installation Type
      • 5.5.6.10 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Installation Type
      • 5.6.1.10 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Installation Type
      • 5.6.2.10 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Installation Type
      • 5.6.3.10 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Installation Type
      • 5.6.4.10 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Installation Type
      • 5.6.5.10 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Astellas Pharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Ferring Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Myriad Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tolmar Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Veru
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Sophiris Bio
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Nymox Pharmaceutical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Spectrum Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Advanced Accelerator Applications
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bavarian Nordic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Progenics Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Onco Genex Pharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Nant Kwest
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Amgen Biosimilars
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Dendreon Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Endo Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Astra Zeneca Biosimilars
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Bristol Myers Squibb Biosimilars
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Novartis Biosimilars
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Sanofi Biosimilars
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us